Isaac S. Ashkenazi is a partner in the Litigation practice of Paul Hastings LLP. Mr. Ashkenazi focuses his practice on complex patent litigation primarily in the pharmaceutical, chemistry, and biotechnology fields. He has experience with a broad range of technologies, including pharmaceutical compounds, proteins, polymers, formulations, and chemical and synthetic processes. Mr. Ashkenazi has represented life sciences companies in patent cases involving a wide variety of therapeutics, including oncology drugs, proton pump inhibitors, sleep agents, respiratory agents, antiemetics, and cholesterol lowering and antidiabetic agents.
Paul Hastings Named Transatlantic IP Team of the Year by The American Lawyer
June 15, 2018
Paul Hastings Wins Law360 Life Sciences Practice Group of the Year for 2017
February 05, 2018
District of New Jersey Prevents Generic Challenger from Using Claim Construction as a Backdoor to Introduce Barred Invalidity Defense
June 16, 2014
Federal Circuit Clarifies That Foreseeability Does Not Preclude the Application of the Doctrine of Equivalents
February 20, 2014
The Federal Circuit Further Clarifies The Obviousness-Type Double Patenting Doctrine For Composition Claims
August 27, 2012
Federal Circuit Signals Reigning in of Janssen and Rasmusson on Enablement/Utility
August 01, 2011
Failure to Launch
April 07, 2011
Federal Circuit Vacates Injunction Against Generic Drug Manufacturer, Determining That A Settlement Agreement Term Is Ambiguous
December 29, 2010
District of New Jersey Resets KUDCos ANDAs Final Approval in Protonix Litigation, Notwithstanding Outstanding Defenses of Teva and Sun
August 19, 2010
Generic Drug Manufacturers Inequitable-Conduct Defenses Dismissed for Failing to Meet Exergens Stringent Pleading Standard
June 08, 2010
Patent Law Reform Bills Introduced in Congress
March 04, 2009
ACI Summit on Biosimilars
June 25, 2018
Law360 Practice Group of the Year Awards for 2017: Life Sciences
Paul Hastings was named as a Practice Group of the Year in Life Sciences by Law360.
The article noted Paul Hastings’ undefeated track record in life sciences cases at the Patent Trial and Appeal Board, including victories on behalf of Acorda Therapeutics, which won four inter partes reviews against Kyle Bass’ Coalition for Affordable Drugs. Law360 also highlighted the representation of Galena Biopharma in a civil-only settlement resolving investigations regarding Galena’s past promotional practices for Abstral, a rapid onset opioid product.
The winners were chosen from nearly 750 submissions, and are recognized as "firms that racked up victories in litigation and closed the big deals to make their mark among clients and throughout the legal industry."
2016 LMG Life Sciences Awards
Hastings was recognized with multiple LMG Life Sciences Awards. Bruce Wexler was named “General Patent
Litigator of the Year – New York” and Naveen Modi was recognized as “Post Grant
Proceedings Attorney of the Year.”
Life Sciences Patent Litigation practice also won awards for two Hatch-Waxman
Impact Cases of the Year, including Helsinn Healthcare SA et al. v. Teva
Pharmaceuticals USA Inc. et al., a win resolving a long-running patent dispute
over Aloxi®, a drug used to treat chemotherapy-induced nausea and vomiting. The
Paul Hastings team representing Helsinn was led by Joseph O’Malley. The firm
was also honored for its work on behalf of Eli Lily in Sanofi-Aventis US LLC et
al. v. Eli Lilly & Co., where Bruce Wexler led the team representing Eli
Lily in litigation regarding the marketing of Basaglar®, its insulin glargine
drug product. The case was settled in late 2015, with the press reporting Eli
Lilly’s ability to launch the drug
LMG Life Sciences Awards 2016
The Firm was shortlisted in four categories for the 2016 LMG Life Sciences Awards, which will be held on September 14 in New York.
Joseph O’Malley was nominated in the “Hatch-Waxman Litigator of the Year – Branded” category, Bruce Wexler was nominated in the “General Patent Litigator of the Year - New York” category, Naveen Modi was nominated in the “Post Grant Proceedings Attorney of the Year” category, and the Firm was nominated in the “Hatch-Waxman Litigation Firm of the Year – Branded” category.
Paul Hastings IP Practice Honored in 2016 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM Patent 1000: The World’s Leading Patent Professionals 2016. The guide ranked the firm’s Nationwide, New York, Washington, D.C., and Georgia IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Robin McGrath, Naveen Modi, Joseph O'Malley, Joseph Palys, Preston Ratliff, Samuel Waxman, and Bruce Wexler were recognized as leading lawyers.
May 27, 2016
Managing IP 2016 North America Awards
Naveen Modi was named Outstanding IP Litigator of the Year – PTAB at Managing IP's 2016 North America Awards. Additionally, Paul Hastings was shortlisted in the US Life Sciences IP Litigation Firm of the Year, Patent Contentious Northeast Firm of the Year, and PTAB Firm of the Year categories.
March 18, 2016
Managing Intellectual Property's 2016 IP Stars
Paul Hastings was recognized nationally in Managing Intellectual Property's 2016 IP Stars rankings. The firm was ranked in Tier 2 in the US Bio/Life Sciences category, Tier 2 in the US PTAB litigation (USPTO) category, and Tier 3 in the US Patent Contentious category.
March 02, 2016
Paul Hastings IP Practice Honored in 2015 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM
Patent 1000: The World’s Leading Patent Professionals 2015. The guide ranked the firm’s Nationwide, New York, and Washington, D.C. IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Naveen Modi, Joseph O'Malley, Steven Park, Jeff Randall, Preston Ratliff, Allan Soobert, and Bruce Wexler were recognized as leading lawyers.
June 17, 2015
Managing IP's 2015 IP Stars
Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Chris Kennerly, Naveen Modi, Joseph O'Malley, and Bruce Wexler were named 2015 IP Stars by Managing Intellectual Property magazine. Nationwide, the firm's Intellectual Property practice was ranked in the Bio/Life Sciences, Copyright, and Patent Contentious categories. In New York, the firm was ranked Highly Recommended in the Patent Contentious category, and in California, the firm was ranked Recommended in the Copyright and Patent Contentious categories.
May 15, 2015
LMG LIfe Science recongnizes Life Sciences IP practice
Paul Hastings' Life Sciences Intellectual Property practice received the highest possible ranking in Legal Media Group’s Life Sciences 2014 guide; as it was ranked “Highly Recommended” in the Hatch-Waxman Patent Litigation (Branded) and General Patent Litigation categories.
Commentary from the guide singled out Joseph O’Malley and Bruce Wexler as “preeminent litigators in the industry” and pointed out Gerald Flattmann’s "ability to serve as lead counsel in important industry cases." The IP practice was also described as having “outstanding teams both for commercial patent litigation as well as in dealing with infringement suits on the branded Hatch-Waxman front.”
October 09, 2014
Legal Media Group's 2013 LMG Life Science Awards
The firm was nominated as a 2013 LMG Life Science nominee in the “Litigation Team of the Year” and “(General) Patent Litigation: Firm of the Year” categories.
August 12, 2013
Intellectual Property Magazine
Intellectual Property Magazine recognized Paul Hastings' IP Pharmaceutical Team as the Pharmaceutical Team of the Year.
November 30, 2010